January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position

tracking biased signaling in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics. 

Novo Nordisk’s amycretin showed up to 24% weight loss, CagriSema delivered 22.7% in Phase 3, and semaglutide

Nordisk, and into biotech at InterAx — where the next challenge is using functional fingerprints to After running her own academic group in Graz, she spent six and a half years at Novo Nordisk in early Nordisk, putting it in an animal, and watching the effect come back exactly as predicted. After working in the US and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer.

Jacek Mokrosiński "Jacek is a Senior Scientist at Novo Nordisk specializing in molecular pharmacology Since 2021, Jacek has been working at Novo Nordisk at its research sites in the UK (Oxford) and the US

My experience in basic research at several universities worldwide and early R&D at Novo Nordisk A/S allowed